DIA

CALL FOR POSTER ABSTRACTS

SUBMISSION DEADLINE: FRIDAY, JUNE 30, 2017

Clinical Trial Disclosure and Data Transparency Conference

SEPTEMBER 14-15 | HILTON WASHINGTON DC/ROCKVILLE HOTEL AND EXECUTIVE MEETING CENTER | ROCKVILLE, MD

CALL FOR POSTER ABSTRACTS

POSTER ABSTRACT SUBMISSION DETAILS and GUIDELINES
SUBMISSION DEADLINE: FRIDAY, JUNE 30

Abstract Submission Overview

Clinical trial sponsors and academia are facing a multitude of new registration requirements in the US and the EU. With evolving requirements come new challenges, creating additional opportunities for knowledge-sharing and necessitating more interaction with peers. The *Clinical Trial Disclosure and Data Transparency Conference* Program Committee welcomes abstracts for both poster and oral presentation consideration. Seize this opportunity to engage and share insights with your fellow attendees by showcasing your research, best practices, or practical applications of related to implementation of the new clinical trial regulations in the US and EU, anonymizing data and data sharing.

Accepted poster abstracts will be displayed during the conference with dedicated poster viewing scheduled to allow attendees to ask questions. Abstracts accepted for oral presentation will be scheduled for a 5-10 minute time slot during one of the conference sessions.

Please note that when you start the abstract submission process, **Poster Abstract** is selected as the default abstract type. This is due to a system limitation. Please specify your preferred format, **Oral Presentation** or **Poster Presentation**, in the Title field. For example, if your presentation title is "Future of Clinical Trial Disclosure" and you prefer oral presentation, please input "Future Clinical Trial Disclosure (Oral)" in the Title field.

General Submission Requirements

(Please read the following instructions carefully. Incorrect or incomplete abstracts will not be considered.)

1. All abstracts must be submitted online to **DIAglobal.org/Abstracts.**
2. Proposed abstract title must reflect the abstract content accurately and concisely.
3. All poster presentations must be noncommercial and scientific in nature and may not be used as a marketing opportunity. Any mention of specific products or and/or services must be limited to generic names, with no inclusion of brand names in any area of the poster, including poster titles and/or handouts. Logos and advertising may not appear anywhere on the poster.
4. Posters must be original in research and include appropriate empirical evidence.
5. Posters must include data, i.e., research results and conclusion for consideration.
6. Preliminary/pilot data is acceptable.

Submission Deadline: Friday, June 30

Notification: Week of July 17

Conference Dates: September 14-15

Location: Hilton Washington DC/Rockville Hotel and Executive Meeting Center

Please submit all abstracts online at: DIAglobal.org/Abstracts

Questions: Contact Kellen Bagnoli at Kellen.Bagnoli@DIAglobal.org

Submit Your Abstract at **DIAglobal.org/Abstracts**

CALL FOR POSTER ABSTRACTS

SUBMISSION DEADLINE: FRIDAY, JUNE 30, 2017

Onsite Requirements

- If an abstract is accepted, the primary author is required to pay the applicable conference registration fee, related expenses, and must be onsite at the meeting during the designated poster session time. *Please note that an individual may only be primary author on one poster.*
- Co-authors who would like to be present for your session must register as well. If none of the authors are able to attend the conference, your poster must be withdrawn from the program.
- Presenters must organize and pay for all shipping arrangements for their poster materials. DIA will not ship or store any materials.
- Presenters must prepare a poster to fit a 4'× 8' poster board.

Eligibility

- Individuals eligible to submit a professional poster include post-doctoral scholars, medical residents, fellows, and professionals whose affiliation is consistent with the mission of DIA.

Required Documentation for All Abstracts

- **Participant Disclosure Information:** All abstract authors must disclose any relevant financial relationships with any commercial interest associated with this activity that exist or have existed within the past 12 months, as well as any discussion of unlabeled or unapproved drugs or devices. If you are proposing an abstract on behalf of the author, as the submitter you will not be asked to disclose. However, should the abstract be accepted, the author will be informed that he or she must complete and submit a Participant Disclosure in order to participate in the program.
- All submitters and authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the Program. Accepted posters will be available on DIA's website for attendee download after the event.

SUBMISSION GUIDELINES

The following information will be requested at the time of submission. ***DIAglobal.org/Abstracts***

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. **Do not wait until the last day.**

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

Submitter or Author Information

Prefix:	Country:
First Name:	Address Line:
Middle Name:	City:
Last Name:	State/Province:
Name Suffix:	Zip/Postal Code:
Degrees:	Phone:
Job Title:	Email:
Company:	

NOTE: If you are submitting on behalf of author, you are considered the SUBMITTER and will need to complete the required information for yourself and also for the AUTHOR. Submitters will be the contact for author regarding the status of the abstract.

Abstract Title (maximum 125 characters, including spaces)
Titles should briefly describe the focus of the abstract as well as accurately reflect the content of the poster.

Primary interest Area
Select the interest area that best relates to your abstract.

Keyword (Maximum 100 characters including spaces)
One or more key words are to be provided to highlight your abstract. Examples of key words: Personalized Medicine, Health Technology Assessment, Clinical Trial Agreements.

Objective (Maximum 300 characters including spaces)
Please provide a one sentence statement of the objective of the abstract.

Method (Maximum 300 characters including spaces)
When, where, and how was the study done? What materials were used or who was included in the study?

Results (Maximum 2000 characters including spaces)
What quantitative data was collected? What answer was found to the research question? What did the study find? Was the tested hypothesis true?

Conclusion (Maximum 2000 characters including spaces)
State what can be concluded from the study and its implications.

Abstracts will be reviewed, and authors will be notified of results the week of July 17, 2017

Submit Your Abstract at **DIAglobal.org/Abstracts**